Literature DB >> 30901004

Is Bone Loss or Devascularization Associated With Recurrence of Osteomyelitis in Wartime Open Tibia Fractures?

Joseph L Petfield1, David R Tribble, Benjamin K Potter, Louis R Lewandowski, Amy C Weintrob, Margot Krauss, Clinton K Murray, Daniel J Stinner.   

Abstract

BACKGROUND: During recent wars, 26% of combat casualties experienced open fractures and these injuries frequently are complicated by infections, including osteomyelitis. Risk factors for the development of osteomyelitis with combat-related open tibia fractures have been examined, but less information is known about recurrence of this infection, which may result in additional hospitalizations and surgical procedures. QUESTIONS/PURPOSES: (1) What is the risk of osteomyelitis recurrence after wartime open tibia fractures and how does the microbiology compare with initial infections? (2) What factors are associated with osteomyelitis recurrence among patients with open tibia fractures? (3) What clinical characteristics and management approaches are associated with definite/probable osteomyelitis as opposed to possible osteomyelitis and what was the microbiology of these infections?
METHODS: A survey of US military personnel injured during deployment between March 2003 and December 2009 identified 215 patients with open tibia fractures, of whom 130 patients developed osteomyelitis and were examined in a retrospective analysis. No patients with bilateral osteomyelitis were included. Twenty-five patients meeting osteomyelitis diagnostic criteria were classified as definite/probable (positive bone culture, direct evidence of infection, or symptoms with culture and/or radiographic evidence) and 105 were classified as possible (bone contamination, organism growth in deep wound tissue, and evidence of local/systemic inflammation). Patients diagnosed with osteomyelitis were treated with débridement and irrigation as well as intravenous antibiotics. Fixation hardware was retained until fracture union, when possible. Osteomyelitis recurrence was defined as a subsequent osteomyelitis diagnosis at the original site ≥ 30 days after completion of initial treatment. This followup period was chosen based on the definition of recurrence so as to include as many patients as possible for analysis. Factors associated with osteomyelitis recurrence were assessed using univariate analysis in a subset of the population with ≥ 30 days of followup. Patients who had an amputation at or proximal to the knee after the initial osteomyelitis were not included in the recurrence assessment.
RESULTS: Of 112 patients meeting the criteria for assessment of recurrence, 31 (28%) developed an osteomyelitis recurrence, of whom seven of 25 (28%) had definite/probable and 24 of 87 (28%) had possible classifications for their initial osteomyelitis diagnosis. Risk of osteomyelitis recurrence was associated with missing or devascularized bone (recurrence, 14 of 31 [47%]; nonrecurrence, 22 of 81 [28%]; hazard ratio [HR], 3.94; 1.12-13.81; p = 0.032) and receipt of antibiotics for 22-56 days (recurrence, 20 of 31 [65%]; nonrecurrence: 37 of 81 [46%]; HR, 2.81; 1.05-7.49; p = 0.039). Compared with possible osteomyelitis, definite/probable osteomyelitis was associated with localized swelling at the bone site (13 of 25 [52%] versus 28 of 105 [27%]; risk ratio [RR], 1.95 [1.19-3.19]; p = 0.008) and less extensive skin and soft tissue injury at the time of trauma (9 of 22 [41%; three definite/probably patients missing data] versus 13 of 104 [13%; one possible patient missing data]; RR, 3.27 [1.60-6.69]; p = 0.001). Most osteomyelitis infections were polymicrobial (14 of 23 [61%; two patients with missing data] for definite/probable patients and 62 of 105 [59%] for possible patients; RR, 1.03 [0.72-1.48]; p = 0.870). More of the definite/probable patients received vancomycin (64%) compared with the possible patients (41%; p = 0.046), and the duration of polymyxin use was longer (median, 38 days versus 16 days, p = 0.018). Time to definitive fracture fixation was not different between the groups.
CONCLUSIONS: Recurrent osteomyelitis after open tibia fractures is common. In a univariate model, patients with an intermediate amount of bone loss and those treated with antibiotics for 22 to 56 days were more likely to experience osteomyelitis recurrence. Because only univariate analysis was possible, these findings should be considered preliminary. Osteomyelitis recurrence rates were similar, regardless of initial osteomyelitis classification, indicating that diagnoses of possible osteomyelitis should be treated aggressively. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30901004      PMCID: PMC6437368          DOI: 10.1097/CORR.0000000000000411

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  34 in total

1.  A score for predicting salvage and outcome in Gustilo type-IIIA and type-IIIB open tibial fractures.

Authors:  S Rajasekaran; J Naresh Babu; J Dheenadhayalan; A P Shetty; S R Sundararajan; M Kumar; S Rajasabapathy
Journal:  J Bone Joint Surg Br       Date:  2006-10

2.  Combat wounds in operation Iraqi Freedom and operation Enduring Freedom.

Authors:  Brett D Owens; John F Kragh; Joseph C Wenke; Joseph Macaitis; Charles E Wade; John B Holcomb
Journal:  J Trauma       Date:  2008-02

3.  Infectious complications of combat-related mangled extremity injuries in the British military.

Authors:  Kate V Brown; Clinton K Murray; Jon C Clasper
Journal:  J Trauma       Date:  2010-07

Review 4.  Antibiotics for treating chronic osteomyelitis in adults.

Authors:  Lucieni O Conterno; Marilia D Turchi
Journal:  Cochrane Database Syst Rev       Date:  2013-09-06

5.  Type III open tibia fractures: immediate antibiotic prophylaxis minimizes infection.

Authors:  William D Lack; Madhav A Karunakar; Marc R Angerame; Rachel B Seymour; Stephen Sims; James F Kellam; Michael J Bosse
Journal:  J Orthop Trauma       Date:  2015-01       Impact factor: 2.512

6.  Infections complicating the care of combat casualties during operations Iraqi Freedom and Enduring Freedom.

Authors:  Clinton K Murray; Kenneth Wilkins; Nancy C Molter; Fang Li; Lily Yu; Mary Ann Spott; Brian Eastridge; Lorne H Blackbourne; Duane R Hospenthal
Journal:  J Trauma       Date:  2011-07

Review 7.  Risk factors for infectious complications after open fractures; a systematic review and meta-analysis.

Authors:  Kirsten Kortram; Hans Bezstarosti; Willem-Jan Metsemakers; Michael J Raschke; Esther M M Van Lieshout; Michael H J Verhofstad
Journal:  Int Orthop       Date:  2017-07-25       Impact factor: 3.075

8.  Impact of joint theater trauma system initiatives on battlefield injury outcomes.

Authors:  Brian J Eastridge; George Costanzo; Donald Jenkins; Mary Ann Spott; Charles Wade; Dominique Greydanus; Stephen Flaherty; Joseph Rappold; James Dunne; John B Holcomb; Lorne H Blackbourne
Journal:  Am J Surg       Date:  2009-12       Impact factor: 2.565

9.  Management of severe open tibial fractures: the need for combined orthopaedic and plastic surgical treatment in specialist centres.

Authors:  S B Naique; M Pearse; J Nanchahal
Journal:  J Bone Joint Surg Br       Date:  2006-03

10.  The nature and incidence of musculoskeletal combat wounds in Iraq and Afghanistan (2005-2009).

Authors:  Philip J Belmont; Brendan J McCriskin; Mark S Hsiao; Robert Burks; Kenneth J Nelson; Andrew J Schoenfeld
Journal:  J Orthop Trauma       Date:  2013-05       Impact factor: 2.512

View more
  3 in total

Review 1.  IDCRP Combat-Related Extremity Wound Infection Research.

Authors:  Joseph L Petfield; Louis R Lewandowski; Laveta Stewart; Clinton K Murray; David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

2.  IDCRP Trauma-Related Infection Research.

Authors:  David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

3.  Modified lateral gastrocnemius myocutaneous flap with extended anterior and/or inferior boundary.

Authors:  Ping Peng; Zhonggen Dong; Jianwei Wei; Lihong Liu; Zhaobiao Luo; Shu Cao; Qiang Xu; Lei Zheng
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.